Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05848700 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT05848700 is a Phase 1 study of Schizophrenia that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 60 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT05848700, a Phase 1 study of Schizophrenia, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
A Clinical Study to learn if SEP-363856 has physical dependence in adults with schizophrenia. This study will be held in approximately 6 study sites in the United States. It will be accepting male and female participants age 18 years to 65 years. Participation will be up to approximately10 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SEP-363856
Study Locations (7)
Arkansas
- Woodland International Research Group, LLC - Little Rock
- Woodland Research Northwest - Rogers
Florida
- Behavioral Clinical Research, Inc - Miami Lakes
- Research Centers of America at Fort Lauderdale Behavioral Health Center - Oakland Park
Georgia
- Atlanta Center for Medical Research - Atlanta
Ohio
- Neuro-Behavioral Clinical Research, Inc - North Canton
Texas
- Pillar Clinical Research, LLC - Richardson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2024-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05848700
The ClinicalTrials.gov registry entry for NCT05848700 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05848700 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Arkansas, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05848700 about?
NCT05848700 is a clinical study titled "A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia". A Clinical Study to learn if SEP-363856 has physical dependence in adults with schizophrenia. This study will be held in approximately 6 study sites in the United States. It will be accepting male and female participants age 18 years to 65 years. Participation will be up to approximately10 weeks.
What is the current status of trial NCT05848700?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-06-21. Estimated completion is 2024-03-15.
What conditions does trial NCT05848700 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT05848700?
The interventions under investigation include: Placebo (DRUG), SEP-363856 (DRUG).
Who is sponsoring clinical trial NCT05848700?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05848700 being conducted?
This trial has 7 study locations across Arkansas, Florida, Georgia, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.